Joe Keegan, CEO of Molecular Devices, greeted analysts at last week’s quarterly conference call by calling the period “the best third quarter in the company’s history.”

Keegan, who has been president and CEO of the 21-year-old company since 1998, was mixed in his outlook, however, noting that the company was surprised by weakness in the drug-discovery market and a slowdown in capital spending for high-dollar tools.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.